Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib With R-ICE in Relapsed or Refractory DLBCL
NCT02219737Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at Day 21 and Toxicity. Started Sep 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02219737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219737.